Report Cover

Asia Pacific Antiviral Drugs Market By Type, By Drug Class, By Indication, By Age Group, Research Report, Country Outlook Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 - 2027


Unprecedented spike in COVID-19 cases in India, China and Australia will bolster Asia Pacific antiviral drugs market share in the next few years. As of mid-March 2021, over 25 million cases were reported in Asia. Rise in hospitalization owing to the pandemic has augmented the demand for anti-viral therapeutics. 
Rampant infectious diseases will bolster the adoption of antiviral drugs across the region. According to the WHO, around 87 million people had hepatitis B's chronic carriers in China. In terms of revenue, Asia Pacific antiviral drugs market is forecast to surpass USD 7.2 billion by 2027.
Increasing cases of hospital-acquired infections have prompted stakeholders to further the manufacturing of antiviral drugs. According to the China Center for Disease Control, around 400 people were found to be HIV positive in 2018 per day. 
Considering the prevalence of HIV AIDS, investments in antiviral drugs will surge dramatically across the region. According to the WHO, there were around 1.25 million people living with HIV infection in China in 2018.The market revenue from the HIV AIDS segment was pegged at over USD 3.2 billion in 2020, attributed to increasing awareness pertaining to treatment therapies. 
End-markets are likely to exhibit traction for protease inhibitors which are highly active antiretroviral therapy drug class. These inhibitors have become highly desirable for their efficaciousness in HIV treatment. Protease inhibitors have gained impetus for efficacious therapy drug, triggering R&D activities and ARV drugs production. The market share from the protease inhibitors segment in APAC was pegged at more than 18% in 2020 and will expand at a substantial rate in the next few years.
Stakeholders are expected to infuse funds in reverse transcription inhibitors on the heels of their effectiveness in the management and treatment of HIV. Rampant disease in emerging economies has fostered the adoption of reverse transcription. It is worth noting that R&D activities in nucleoside and non-nucleoside reverse transcriptase inhibitors will augur well for the industry outlook. APAC antiviral drugs market share from the reverse transcriptase inhibitors segment stood at more than 40% in 2020 and will witness an appreciable gain by 2027.
Market uptake of generic antiviral drugs will be noticeable owing to heightened awareness and availability of generic therapeutics. Moreover, robust government initiatives and policies to provide high cost treatment at affordable prices to low-income group people will bode well for the industry size expansion. The market size from the generic antiviral drugs segment was valued at more than USD 1.5 billion in 2020 and will rise notably in the ensuing period.
Manufacturing of antiviral drugs emphasizing adult age-group will gain prominence in India and China. For instance, the WHO has joined hands with governments and other partners across the Western Pacific to prevent, test and treat hepatitis among adults. Based on share, the adult segment logged 30% in 2020 and will rise at a considerable pace through 2027.
Leading companies are likely to further their investments in India following the surge in COVID-19 cases and HIV AIDS. Specifically, the Minister of Health and Family Welfare introduced a new test-and-treat policy in April 2017 for rendering access to HIV treatment in the nation. India antiviral drugs market size is forecast to surpass USD 1.2 billion by 2027, partly attributed to improving healthcare facilities.
The China market is likely to provide revenue-boosting opportunities following the growth in government funding and infrastructural development. The mainland will further witness injection of funds in R&D activities. China antiviral drugs market revenue share was pegged at more than 16% in 2020 and will grow notably in the next few years.
Key industry players in the landscape are GlaxoSmithKline, Merck & Co., AbbVie Inc., Aurobindo Pharma Ltd and Bristol-Myers & Co., among others. These companies are likely to focus on R&D activities and manufacturing developments.
Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Forecast assumptions

1.3    Data sources

1.3.1    Secondary

1.3.1.1    Paid sources

1.3.1.2    Unpaid sources

1.3.2    Primary

Chapter 2   Market Summary

2.1    Asia Pacific anti-viral drugs industry summary, 2016 - 2027

2.1.1    Country trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age group trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 - 2027 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Increasing prevalence of viral infections including COVID-19

3.3.1.2    Presence of pipeline products for HIV treatment

3.3.1.3    Increasing geriatric population

3.3.2    Industry pitfalls & challenges

3.3.2.1    Presence of generics

3.3.2.2    Rising awareness about preventive drugs treatment

3.3.2.3    Drug resistance

3.3.2.4    High cost of HIV and Hepatitis drug treatment

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter's analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   Asia Pacific Anti-viral Drugs Market, By Drug Class

4.1    Market trends

4.2    DNA polymerase inhibitors

4.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3    Reverse transcriptase inhibitors

4.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.4    Protease inhibitors

4.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.5    Neuraminidase inhibitors

4.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.6    Others

4.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 5   Asia Pacific Anti-viral Drugs Market, By Indication

5.1    Market trends

5.2    Influenza

5.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3    HIV/AIDS

5.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.4    Hepatitis

5.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.5    Herpes Simplex Virus

5.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.6    Coronavirus Infection

5.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.7    Others

5.7.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 6   Asia Pacific Anti-viral Drugs Market, By Type

6.1    Market trends

6.2    Branded

6.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.3    Generic

6.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 7   Asia Pacific Anti-viral Drugs Market, By Age Group

7.1    Market trends

7.2    Adult

7.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.3    Pediatric

7.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.4    Geriatric

7.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 8   Asia Pacific Anti-viral Drugs Market, By Country

8.1    Market trends

8.2    Japan

8.2.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.2.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.2.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.2.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.3    China

8.3.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.3.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.3.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.3.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.4    India

8.4.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.4.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.4.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.4.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.5    Australia

8.5.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.5.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.5.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.5.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.6    South Korea

8.6.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.6.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.6.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.6.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.7    Singapore

8.7.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.7.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.7.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.7.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.8    Indonesia

8.8.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.8.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.8.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.8.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.9    Thailand

8.9.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.9.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.9.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.9.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.10    Malaysia

8.10.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.10.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.10.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.10.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.11    Philippines

8.11.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.11.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.11.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.11.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

Chapter 9   Company Profiles

9.1    Gilead Sciences, Inc

9.1.1    Business overview

9.1.2    Financial data

9.1.3    Product landscape

9.1.4    Strategic outlook

9.2    Johnson & Johnson

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Product landscape

9.2.4    Strategic outlook

9.3    GlaxoSmithKline

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Product landscape

9.3.4    Strategic outlook

9.4    AbbVie Inc.

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Product landscape

9.4.4    Strategic outlook

9.5    Merck & Co.

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Product landscape

9.5.4    Strategic outlook

9.6    Bristol Myers Squibb

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Product landscape

9.6.4    Strategic outlook

9.7    Aurobindo Pharma Ltd.

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Product landscape

9.7.4    Strategic outlook

9.8    Cipla Inc.

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Product landscape

9.8.4    Strategic outlook

9.9    Sun Pharmaceutical Industries Ltd

9.9.1    Business overview

9.9.2    Financial data

9.9.3    Product landscape

9.9.4    Strategic outlook

9.10    Viatris Inc.

9.10.1    Business overview

9.10.2    Financial data

9.10.3    Product landscape

9.10.4    Strategic outlook


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:
Publisher: Graphical Research
Chat with us